Retesting of breast cancers initially classified as ER−/PR+ by IHC with transcriptional-based methods like the Oncotype DX assay is essential for oncologists to accurately select treatment, reduce patient risks from over- and under-treatments and to improve patient outcomes. The gene discussed is PGR; the disease is breast cancer.